Live Breaking News & Updates on Condensed Financial|Page 11

Stay updated with breaking news from Condensed financial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

1st Capital Bank: 1st Capital Bancorp Announces Fourth Quarter 2020 Financial Results


1st Capital Bank: 1st Capital Bancorp Announces Fourth Quarter 2020 Financial Results
SALINAS, CA / ACCESSWIRE / January 29, 2021 /
1st Capital Bancorp (OTC PINK:FISB) reported unaudited net income of $1.59 million for the three months ended December 31, 2020, an increase of 67.1% compared to net income of $953 thousand in the third quarter of 2020 and a decrease of 8.1% compared to net income of $1.73 million in the fourth quarter of 2019. Earnings per share were $0.28 (diluted) for the fourth quarter of 2020, compared to $0.17 (diluted) for the prior quarter, and $0.31 (diluted) for the fourth quarter of 2019.
Unaudited net income for the year ended December 31, 2020 was $4.50 million, a decrease of 36.5% compared to net income of $7.09 million for the year ended December 31, 2019. Year-to-date earnings per share were $0.81 (diluted) and $1.27 (diluted) for the years ended December 31, 2020 and 2019, respectively. ....

State Of California , United States , San Benito County , San Benito , King City , Santa Cruz County , San Francisco , Michaelj Winiarski , Kostenloser Wertpapierhandel , Jond Ditlevsen , Luis Obispo , Daler Diederick , Samueld Jimenez , Us Department Of Agriculture , Federal Reserve Bank , Capital Bank The , Capital Bank , Nine Of The Bank , Us Small Business Administration , Home Loan Bank , Paycheck Protection Program , Capital Bancorp , Santa Cruz , San Luis Obispo , Protection Program , Business Administration ,

Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.


13
1Refers to continuing operations as defined on page 43 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions.
2Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
3 Please see detailed guidance assumptions on page 8 including the forecast assumption that we see a continuation of the return to normal global healthcare systems including prescription dynamics by mid 2021. In addition, we assume that no Gilenyaand noSandostatinLAR generics enter in 2021 in the US. ....

United States , Charlesl Sawyers , Bridgette Heller , Bertrand Bodson , Kesimptaandentresto Hfp , Robert Weltevreden , Elizabeth Doherty , Patrice Bula , Nancyc Andrews , Jakavi Gv , Simon Moroney , Promacta Revolade , Frans Van Houten , Joerg Reinhardt , Srikant Datar , Enrico Vanni , Moody Investors Service , Novartis Group , Compensation Committee , Customer Technology Solutions , Novartis Executive Committee On , Alcon Inc , Committee Novartis , Sandoz Division , Committee Of Novartis , International Financial Reporting Standards ,

Novartis International AG: Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.


Novartis International AG: Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.
Pharmaceuticals BU grew 5% (cc) driven by
Entresto (+44% cc),
Cosentyx (+13% cc),
Xiidra acquisition (+95% cc)
Promacta/Revolade (+23% cc),
Piqray (reaching USD 0.3 billion)
Sandoz sales were in line (cc, -1% USD), with Biopharmaceuticals growing 19% (cc)
COVID-19 negatively impacted demand, particularly: ophthalmology, dermatology and Sandoz retail
Core operating income² grew 13% (cc, +9% USD) and Innovative Medicines and Sandoz core margin improved to 35% and 24% of sales respectively, driven by sales growth, lower spend and productivity
Continued transformation of Manufacturing and Business Services contributing to core margin expansion ....

United States , New Zealand , San Antonio , Entresto Hfp , Patrice Bula , Nancyc Andrews , Simon Moroney , Gleevec Glivec , Exjade Jadenu , Charlesl Sawyers , Bridgette Heller , Bertrand Bodson , Elizabeth Doherty , Robert Weltevreden , Jakavi Gv , Promacta Revolade , Frans Van Houten , Joerg Reinhardt , Afinitor Votubia , Srikant Datar , Enrico Vanni , Moody Investors Service , Novartis Group , American College Of Rheumatology , Compensation Committee , American Society Of Hematology ,